Paciente feminina, 70 anos, apresentou-se com queixas de prurido ocular à esquerda, lacrimejamento e hiperemia há 2 meses. Ao exame físico, apenas hiperemia conjuntival discreta. Foi solicitada biópsia, que sugeriu a hipótese de pseudolinfoma pela insuficiên-cia de critérios classificatórios. Após um ano a paciente retornou com os mesmos sintomas e proptose ocular à esquerda, associado a proliferação de aspecto linfático em conjuntiva bulbar, com presença de vasos sanguíneos, ocupando toda região superior e maior parte da medial, se estendendo até o limbo, sem oclusão do eixo visual e mobilidade ocular extrínseca preservada. Nova biópsia e imuno-histoquímica, foram compatíveis com linfoma de células B da zona marginal. Foram realizadas tomografias computadorizadas (TC) de crânio, pescoço e órbitas, revelando aumento do volume do músculo reto superior esquerdo, com intensa impregnação pelo contraste, acometendo ventre e tendão, com borramento de gordura adjacente. Foram programados 6 ciclos de quimioterapia com ciclofosfamida, doxorrubicina, vincristina e prednisona, CHOP, a cada 21 dias. Houve melhora dos sintomas oculares após o primeiro ciclo. Após o quarto, nova TC de órbitas evidenciou regressão do espessamento do músculo reto superior esquerdo, ainda melhor na TC realizada após o sexto ciclo. Os linfomas MALT são responsáveis por 5-17% de todos os casos de LNH, respondem por mais de 90% dos linfomas que acometem os anexos oculares, mas podem se originar em diversos tecidos. Devido a raridade da doença, carecem estudos prospectivos randomizados que definam um consenso terapêutico. A literatura sugere que o tratamento deve ser individualizado.
INTRODUCTION
T he orbital lymphoma is rare and comprises approximately 10% of all orbital neoplasms. Most of the non-Hodgkin's lymphomas (NHL) in the ocular adnexa are extranodal B-cell marginal zone lymphomas, also known as MALT lymphomas. (1) (2) (3) (4) Marginal zone lymphomas (MZL) originate from memory B lymphocytes normally present in a distinct micro-anatomic compartment called the marginal zone in the secondary lymphoid follicles. According to the site of origin and molecular characteristics, they can be classified into 3 subtypes according to the World Health Organization: extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT), splenic marginal zone lymphoma and nodal marginal zone lymphoma. (5) MALT lymphomas account for 5-17% of all NHL cases, depending on the series. (6) In relation to the sites of involvement, they account for 50% of all gastric lymphomas and more than 90% of lymphomas affecting the eye adnexa, but they may originate in many other epithelial tissues as salivary gland, thyroid, lung, breast, skin, liver, small intestine, urogenital system and dura mater. Most cases involve adults over 60 years old, with a slight predominance for women. (7) (8) (9) It is theorized that the lymphoid hyperplasia occurs in response to stimulation by antigens, followed by additional oncogenic events including chromosome abnormalities perpetuating the disease development. (10) Four recurrent chromosomal translocations were found: t(11;18) (q21;q21), t(14;18)(q32;q21), t(1;14)(p22;q32) e t(3;14)(p13;q32) resulting in the activation of NF-kappa B, a factor involved in the survival of these cells. (11) (12) (13) A variety of autoimmune diseases have been associated to the development of MZL, like rheumatoid arthritis, Sjogren's syndrome, systemic lupus erythematosus, Wegener's granulomatosis, and Hashimoto's Thyroiditis, and autoimmune mechanisms may play a role in pathogenesis. (14) This study aims at describing a case of ocular marginal zone B cells, emphasizing the clinical epidemiological characteristics and treatment options described in the literature, since there are no prospective randomized studies comparing the therapeutic options.
CASE REPORT
Female patient, 70 years old, sought treatment in February 2012, complaining of itchy left eye, with tearing and redness for 2 months. The physical examination showed only a discreet conjunctival hyperemia. The left eye biomicroscopy showed decreased endothelial density to the age. Biopsy was requested, and the sample represented tenon of limbal region, mucous and intermuscular membrane, in which immunohistochemistry was performed and identified lymphoepithelial infiltration, suggesting the hypothesis of pseudolymphoma due to insufficient classification criteria. There was follow-up discontinuity, so that in September 2013 the patient returned with the same symptoms and eye left proptosis associated to extensive proliferation of the lymphatic aspect in bulbar conjunctiva ( Figures 1A and 1B) , with the presence of blood vessels occupying the entire superior region and most of the medial region, extending into the limbo, but without occlusion of the visual axis and extrinsic ocular motility (Table 1) , which was compatible with Bcell lymphoma of extra nodal marginal zone. Studies were carried out with computed tomography (CT) of skull, neck and orbits, revealing an isolated finding of increased volume of the left superior rectus muscle, with intense impregnation by contrast, affecting the womb and tendon, with blurring of adjacent fat ( Figures 5A and 5B) . Once identified the nature of the disease, stage IE (Ann Arbor System), and considering the location of the lesion, 6 cycles of were programmed with cyclophosphamide, doxorubicin, vincristine and prednisone, CHOP, every 21 days. The patient developed with improvement of ocular symptoms and regression of proliferation in the bulbar conjunctiva right after the first cycle. After the fourth cycle, a new CT of the orbits showed regression of the thickening of the left superior rectus muscle, which was even better in the CT carried out after the sixth cycle ( Figures 6A and 6B ). 
DISCUSSION
The clinical presentation depends on the site involved; in the case of ocular adnexa, the patient may have Sjögren's syndrome, conjunctival hyperemia, proptosis, chemosis or palpable mass of indolent growth. (15, 16) The natural history of the disease has indolent character, and differs in clinical and biological aspects when compared to MALT lymphomas of the gastrointestinal tract. An example is the strong association of chronic antigenic stimulation for H pylori, well established in the development of gastric MALT lymphoma. Although there are theories explaining the pathogenesis of the disease involving autoimmune or infectious stimuli, extra gastric lymphomas did not regress after eradication of H pylori, but in some countries, the ocular lymphoma adnexa have been associated to infection by Chlamydia psitacci and regressed after antibiotic therapy. (17) Histological findings consist of poorly defined follicular areas consisting of monocytoid B cells with large nuclei. An important feature is the lympho-epithelial lesions, defined by the distortion of the epithelial structures by neoplastic lymphoid cell aggregates. (18) An histologic transformation for large-cell lymphoma is reported in approximately 10% of cases. (19, 20) On immunohistochemistry, the presence of an intraepithelial lymphocyte population positive for antigens associated to cells B CD20, CD19, CD22, CD79a and negative for CD3, CD21, CD35, and which is generally negative for CD5 CD10, CD23, support the diagnosis of MALT lymphoma. (21) The management of non-gastric disease is not clearly defined, and retrospective studies showed that patients treated with radiation therapy, surgery and chemotherapy, alone or in combination, resulted in excellent control of the disease and survival rates, and no modality proved to be superior to another. (16, 19, 20, 22) Currently the guidelines recommend that the therapeutic decision is based on the stage of the disease, determined by the Ann Arbor system (Table 2), the site of the tumor and the clinical and individual characteristics of the patient. (21) Imaging studies should include a tomography without contrast of the thorax, abdomen and pelvis to exclude distance Table 1 Immunophenotypic markers analyzed in the clinical case
Furthermore, patients with multifocal disease should have aspirate and bone marrow biopsy. (23) Patients with limited disease, stages IE and IIE, should consider locoregional radiotherapy with doses between 25-30 Gy. (14, 24) This lymphoma is very sensitive to radiation, and the dose should not exceed 30Gy due to the risk of damage to the ocular structures. Studies have demonstrated complete response in more than 90% of cases with this approach. (25) However, radiotherapy is not universally accepted for patients with MZL of ocular adnexa. (26) (27) (28) Bennett et al. reported that the chemotherapy regimen was effective in the primary high-grade orbital lymphoma or with distance disease. (29) Alkylating agents such as cyclophosphamide and chlorambucil result in a high rate of disease control, and can be used alone or in combination. (30) (31) (32) Phase II studies using monoclonal antibodies anti-CD20, Rituximab, showed a response rate of 70%, representing one more option in the treatment of systemic disease. (33) Chemotherapeutic drugs used for the treatment of indolent NHL have also demonstrated high effectiveness. In retrospective analysis, 26 patients with MALT lymphoma in recurrence have received rituximab and cyclophosphamide, doxorubicin/ mitoxantrone, vincristine and prednisone (R-CHOP/R-CNOP), 77% of which achieved complete remission and 23% partial remission. Primarily hematologic toxicity was reported with these schemes. (34) The treatment of patients with advanced stage extranodal LMZ is not clearly defined, and most of the data in this population comes from a retrospective series or extrapolation of data from other indolent NHL. These patients are usually treated similarly to those with advanced stage follicular lymphoma, including immunotherapy with rituximab, with or without chemotherapy. (19) 
